The Senate last night voted 98-2 to approve the Patient Right to Know Drug Prices Act (S. 2554), a bill that would prohibit private health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance. Some health insurance contracts prevent pharmacists from informing patients when the cash price for their prescription costs less than their insurance cost-sharing arrangement unless the individual asks. The Senate earlier this month passed a similar bill that applies to patients in Medicare Advantage and Medicare Part D plans. The House Energy and Commerce Committee last week approved similar legislation for Medicare and private health plans.

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health today voted to advance to the full committee a number of AHA-supported bills focused on maternal health…
Headline
The House Appropriations Committee today voted 33-25 to approve legislation that would provide $253.8 billion in funding for the departments of Labor,…
Headline
Congress should not extend Medicare sequestration to help pay for the bipartisan infrastructure framework because health care providers cannot sustain…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
The AHA today released a new episode of PowerPlay, the on-demand video series that connects AHA members to major players in policy, politics and science. The…